Rosamond Deegan is the founder of OMass Technologies. OMass Technologies has raised $160M in total funding. Latest round: Series B.
Rosamond Deegan, also known as Ros Deegan, is the Chief Executive Officer of OMass Therapeutics, an Oxford-based biotechnology company focused on developing treatments for rare diseases and immunological conditions. She spearheaded the company's shift from a service-based model to therapeutics, expanding the team to 40 individuals and securing a significant Series A funding increase. Appointed CEO in May 2019, Deegan has guided OMass Therapeutics to a successful ~$100M Series B financing in 2022.
Full founder directory · Investor directory · Company funding database · Fundraising library